## GRAL: GRAIL, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.8% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $110 | $85 | +29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 4 |

**Top Holders:**
- Blackrock Inc.: 6.3% (+0.7%)
- Primecap Management : 5.2% (-1.6%)
- CRCM LP: 4.7% (-49.5%)
- Vanguard Group Inc: 4.7% (-4.5%)
- Baker Bros. Advisors: 4.2% (0.0%)

### Key Risks

1. High beta (3.53) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. High short interest (15.6%, 4.5 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (7.6x), low leverage (D/E 0.16). Analyst sentiment positive (1 raises, avg +29%). Institutional flow bullish (4 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.6B |
| Beta | 1.00 |
| 52W Range | $16.56 - $115.76 |
| Short Interest | 15.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -6.7% to -0.8% (+5.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.79x) but short-term weakness (below SMA20). MACD histogram bearish (-1.31), momentum weakening. RSI neutral at 49. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.82% (CS: 53) | Neutral |
| RSI_14 | 49.3 | Neutral |
| MACD Histogram | -1.31 | Bearish |
| vs SMA20 | 0.943x | Below |
| vs SMA50 | 1.018x | Above |
| vs SMA200 | 1.790x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.39
- **Stop Loss:** $78.27 (14.4% risk)
- **Target:** $104.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 91
- **Position Value:** $8,316.49
- **Portfolio %:** 8.32%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-19 (Est: $-2.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-3.27 | $-2.46 | +24.7% |
| 2025Q2 | $-3.56 | $-3.18 | +10.8% |
| 2025Q1 | $-3.80 | $-3.10 | +18.5% |
| 2024Q4 | $-4.97 | $-2.89 | +41.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*